Screening characteristics of PSEN1 E280A mutation carriers and non-carriers in the API Autosomal Dominant Alzheimer¿s Disease Colombia Trial

ABSTRACT: Background: The Colombia Alzheimer’s Prevention Initiative (API) Registry was aresource for enrollment into the API Colombia clinical trial. Potentially eligible can-didates from the Colombia API Registry went through a prescreening and then in-person screening process with the goal of enr...

Full description

Autores:
Ramos Pérez, Claudia Patricia
Lopera Restrepo, Francisco Javier
Ríos Romenets, Silvia
Giraldo Chica, Margarita
Acosta Baena, Natalia
Tobón Quintero, Carlos Andrés
López Reyes, Hugo Elías
Aguirre Acevedo, Daniel Camilo
Muñoz Zapata, Claudia Cecilia
Henao Arboleda, Eliana
Tirado Pérez, Victoria Claudia
Ospina Lopera, Paula Andrea
Sink, Kaycee M.
Hu, Nan
Langbaum, Jessica B.
Reiman, Eric M.
Tariot, Pierre N.
Bocanegra García, Orfa Yamile
Tipo de recurso:
Article of journal
Fecha de publicación:
2020
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/43060
Acceso en línea:
https://hdl.handle.net/10495/43060
Palabra clave:
Mutación
Mutation
Enfermedad de Alzheimer
Alzheimer Disease
Colombia
https://id.nlm.nih.gov/mesh/D009154
https://id.nlm.nih.gov/mesh/D000544
https://id.nlm.nih.gov/mesh/D003105
Rights
openAccess
License
http://creativecommons.org/licenses/by-nc/2.5/co/
Description
Summary:ABSTRACT: Background: The Colombia Alzheimer’s Prevention Initiative (API) Registry was aresource for enrollment into the API Colombia clinical trial. Potentially eligible can-didates from the Colombia API Registry went through a prescreening and then in-person screening process with the goal of enrolling them in the API ADAD ColombiaTrial. Analysis of screening data might provide additional information to consider forother AD prevention trials. We present descriptive screening data from the API ADADColombia trial in Presenilin 1 (PSEN1) E280A mutation carriers vs non-carriers.Method: Consent was obtained from 319 potentially eligible participants after pre-screening. Screening data from 315, including 210 mutation carriers, were used tocompare demographics, medical comorbidities, toxic and reproductive antecedents,selected clinical, functional, and anthropometric measurements, vital signs, and brainMRI and laboratory results in the mutation carrier and non-carrier groups. Descriptivestatistics comparing mutation carriers and non-carriers were performed using gener-alized linear regression models using link function according to whether the outcomewas categorical or numerical. Results were adjusted for age, sex, level of education,depression or body mass index (BMI) depending upon which measurements were com-pared.